The technology described herein relates to a set of mechanisms that enable biochemical reactions within a closed container, e.g., a tube, using a screw turn mechanism or other mechanism to allow a user to easily and reliably advance the reaction in a manual, stepwise process.
In some reactions, for example those in which DNA is amplified (e.g., copied exponentially), it is useful to keep the products of the reaction enclosed. In the case of highly sensitive amplification of specific nucleic acid targets, as is increasingly common in the diagnosis of SARS-CoV-2 and other infectious disease with Nucleic Acid Amplification Tests (NAATs), any amplification product released resembles the template (target) itself, and so can contaminate future tests and yield false positives. In other applications, the final mixture may be toxic or sensitive to surrounding chemicals or the environment. Moreover, it is common in modern usage to use very small volumes in biochemical reactions, including 50 μl, 10 μl, or less, where surface tension, viscosity, and hydrophobic/hydrophilic forces are high compared to mass effects such as weight and inertia. Further, the ratio of inertial forces to viscous forces are generally low, causing mixing processes to be laminar and often incomplete. Thus, there is a need in the art for devices, reaction vessels and/or containers that provide reliable reactions while controlling for operational factors that could cause testing errors.
According to one implementation of the present disclosure, a device for performing a multi-step assay comprises a tube, a cap, an insert, and a reaction container. The tube includes a lateral flow strip disposed therein. The cap is coupled to the tube and includes a hollow interior defined therethrough. The insert is configured to be partially received within the hollow interior of the cap. The reaction container includes a cavity configured to store one or more fluids therein. The reaction container is rotatably coupled to the cap, such that rotation of the cap relative to the reaction container causes (i) the one or more fluids to be mixed, and (ii) at least a portion of the mixed fluids to be delivered from the reaction container to the lateral flow strip, via the insert.
In some aspects of the implementation, the reaction container includes a first well storing a first reagent, a second well storing a second reagent, a third well storing a buffer, and a seal covering an opening of the third well. In some aspects of the implementation, the insert includes a body, a displacing bump extending from the body, a brush extending from the body and an aperture defined through the body. In response to the reaction container being rotated relative to the cap to a first position, the brush aids in mixing the first reagent stored in the first well and the second reagent stored in the second well. In response to the reaction container being rotated relative to the cap from the first position to the second position, the displacing bump is configured to break the seal of the third well to mix the buffer with the mixed first reagent and second reagent. In response to the reaction container being rotated relative to the cap from the second position to the third position, the aperture of the body is configured to deliver the mixed first reagent, second reagent, and buffer from the reaction chamber to the lateral flow strip.
In some aspects of the implementation, the reaction container is configured to store a first reagent, and the insert includes a blister pack configured to store a buffer. The reaction container includes a protrusion configured to engage the blister pack and cause mixing of the first reagent and the buffer in response to the reaction container being rotated relative to the cap toward a first position.
According to another implementation of the present disclosure, a device for performing a multi-step assay comprises a cap, a lateral flow strip, a plunger assembly, a reagent insert, and a reaction container. The cap includes a hollow interior defined therethrough. The plunger assembly includes a primary plunger and a secondary plunger, and is configured to be received within the hollow interior of the cap. The reagent insert includes a primary aperture, a secondary aperture, a slot, and a seal. The primary aperture is configured to store a first reagent. The secondary aperture is configured to store a second reagent. The slot is configured to receive a portion of the lateral flow strip therein. The seal is positioned such that it covers an end of both the primary aperture and the secondary aperture. The reaction container includes an internal cavity configured to store a buffer and receive a portion of the reagent insert therein. In response to rotation of the reaction container relative to the cap to a first position, the primary plunger pierces the seal to mix the first reagent and the buffer. In response to rotation of the reaction container relative to the cap from the first position to a second position, the secondary plunger pierces the seal to mix the second reagent with the mixed first reagent and buffer. In response to rotation of the reaction container relative to the cap from the second position to the third position, the mixed first reagent, second reagent, and buffer are transported from the reaction container to the lateral flow strip through the reagent insert.
According to a further implementation of the present disclosure, a device for performing one or more tests on one or more samples comprises a collection assembly and a reaction container. The collection assembly includes a handle and a plurality of collection swabs extending from the handle. The reaction container includes a plurality of reaction chambers. Each of the plurality of reaction chambers is associated with a corresponding one of the plurality of collection swabs. In response to a configuration of the device moving from an unassembled configuration to an assembled configuration, the collection assembly is coupled to the reaction container, and each of the plurality of reaction chambers at least partially houses the corresponding one of the plurality of collection swabs therein.
Additional aspects of the present disclosure will be apparent to those of ordinary skill in the art in view of the detailed description of various implementations, which is made with reference to the drawings, a brief description of which is provided below.
Features and advantages of the present disclosure will become more apparent from the following detailed description of exemplary implementations thereof taken in conjunction with the accompanying drawings in which:
While the present disclosure is susceptible to various modifications and alternative forms, specific implementations have been shown by way of example in the drawings and will be described in detail herein. It should be understood, however, that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.
While this invention is susceptible of embodiment in many different forms, there is shown in the drawings and will herein be described in detail preferred aspects of the invention with the understanding that the present disclosure is to be considered as an exemplification of the principles of the invention and is not intended to limit the broad aspect of the invention to the aspects illustrated. For purposes of the present detailed description, the singular includes the plural and vice versa (unless specifically disclaimed); the words “and” and “or” shall be both conjunctive and disjunctive; the word “all” means “any and all”; the word “any” means “any and all”; and the word “including” means “including without limitation.”
In some multi-step reactions, it is desirable that stepwise reactions be easily controlled by untrained or lightly trained (non-expert, non-professional) users, ranging from healthcare workers operating point of care tests to consumers testing at home, and so should be straightforward and easy to control. In some implementations, reactant amounts may be pre-metered and there would be no need for precise operation on the part of the user. This contrasts with the pipetting of small volumes with user-calibrated equipment, with which errors are frequently made. A desirable product may include precise operation internally with only straightforward, coarse treatment by the user. It is desirable for reactions including the movement of small volumes of reagents to be driven by mechanisms that provide precise volume movement, timing, and mixing.
Provided herein are mechanisms and devices that enable reliable, consistent multi-step reactions within closed reaction containers, moving and mixing volumes of 10-200 μl with a simple rotation mechanism. Implementations of the various aspects described herein can be used for diagnostic purposes, such as performing amplification reactions to detect a target where the problems of contamination with amplicons and ease of use are critical. Amplification reactions that can be performed can include a polymerase chain reaction (PCR); variants of PCR such as Rapid amplification of cDNA ends (RACE), ligase chain reaction (LCR), multiplex RT-PCR, immuno-PCR, SSIPA, Real Time RT-qPCR and nanofluidic digital PCR; loop-mediated isothermal amplification (LAMP); recombinase polymerase amplification (RPA); isothermal amplification; Helicase-dependent isothermal DNA amplification (HDA); Rolling Circle Amplification (RCA); Nucleic acid sequence-based amplification (NASBA); strand displacement amplification (SDA); nicking enzyme amplification reaction (NEAR); polymerase Spiral Reaction (PSR); and others. In one example, devices can be used to detect a target nucleic acid for a diagnosis, e.g., for a SARS-CoV-2 diagnosis. In some implementations, a rotation or screw mechanism is contemplated for advancing a series of reactions. Some implementations allow for the preparation and addition of the third reagent at the point of use, and uses a brush-like mechanism to combine the smaller volumes and ensure their mixture. In some implementations, a positive displacement mechanism to add small volumes and beads to ensure effective mixing is used. In some implementations, seals (such as O-rings) can be used to prevent leakage. In some implementations, some reagents can be packaged at the factory and maintained in ‘blister pack’ compartments, e.g., under a foil seal that can be pierced during activation. In some implementations, the components can be designed to be injection molded in polyethylene or other plastics. Some implementations utilize a test strip, such as a lateral flow strip. In these implementations, the component housing the lateral flow strip is at least partially transparent, such that the lateral flow strip can be visually examined. In some implementations, an overall size of an exemplary device is approximately 20 cm in height.
In the illustrated implementation, the tube 110 and the cap 120 are unitary or monolithic. In this implementation, the tube 110 and the cap 120 are formed (for example via injection molding) as a single piece. In other implementations, the tube 110 and cap 120 are formed separately, and can then be coupled to each other. The cap 120 is formed from a cylindrical wall 122 that defines a hollow interior 124. The hollow interior 124 is generally open at both ends 121A, 121B of the cap 120, such that the hollow interior 124 is defined all the way through the cap 120. One end 121A of the cap 120 includes slots 126A and 126B, while the other end 121B of the cap 120 includes internal threads 128. As explained in more detail herein the slots 126A and 126B are configured to engage the insert 130, such that the insert 130 is rotationally locked to the cap 120 and cannot rotate relative to the cap 120.
The insert 130 is formed from a body 132 that includes one or more passageways or apertures 134 defined all the way through the body 132, from a first end 133A to a second end 133B. The body 132 of the insert 130 is configured to be received in the hollow interior 124 of the cap 120. The insert 130 further includes a displacing bump 136 and a brush 138. The displacing bump 136 and the brush 138 each extend away from the second end 133B of the body 132. The displacing bump 136 generally extends from the center of the second end 133B of the body 132. The displacing bump 136 is depicted as having a generally rectangular shape. However, the displacing bump 136 can have other shapes as well. For example, the displacing bump 136 can have a square shape, a cylindrical shape, a conical shape, a triangular shape, a trapezoidal shape, a frustum shape, etc.
In
The reaction container 140 includes walls 142A and 142B that together define an internal cavity 143. In the illustrated implementation, the reaction container 140 has a circular cross-section. Thus, wall 142A can be a hollow cylindrical tube, while wall 142B is a circular base. An O-ring 145 can be located on the exterior circumference of the wall 142A, at a first end 141A of the reaction container 140. The reaction container 140 further includes external threads 144 located between the first end 141A and the second end 141B of the reaction container 140, so that the reaction container 140 can be coupled to the cap 120 via a threaded connection. The external threads 144 are configured to engage with the internal threads 128 of the cap 120, to thereby rotatably couple the reaction container 140 to the cap 120. The internal threads 128 and the external threads 144 could both be left-handed threads or both be right-handed threads. Moreover, in some implementations, the internal threads 128 and the external threads 144 could both be modified such that threads 128 are external threads and threads 144 are internal threads.
The reaction container 140 also contains a plurality of wells that includes wells 146A and 146B and central well 148. The wells 146A, 146B, and 148 are configured to store various substances therein, such as buffers and reagents. In one implementation, well 146A stores a recombinase polymerase amplification (RPA) reagent, well 146B stores a sodium dodecyl sulfate (SDS) reagent, and central well 148 stores an exonuclease reaction buffer.
Generally, the sample being tested is placed into the reaction container 140 prior to performing the assay, for example via the use of a pipette. In some implementations, the sample may be placed into one or both of the wells 146A and 146B. In other implementations, a portion of the sample is disposed in the hollow interior of the reaction container 140 above the wells 146A and 146B. In the illustrated implementations, wells 146A and 146B are separate wells that are not fluidly coupled together. However, in other implementations, the reaction container 140 may include a single toroidal well, instead of the two separate wells 146A and 146B.
In some implementations, the wells 146A and 146B are open at one end, with the other end being formed from the structure of the reaction container 140. In some implementations, the central well 148 is open at both ends (e.g., neither end of the central well 148 is formed from the structure of the reaction container 140. In these implementations, the reaction container 140 can further include a seal 149A covering one end of the central well 148, and a removable cap 149B covering the other end of the central well 148. In some implementations, seal 149A is a foil seal.
In
In
In
In
Once the mixture reaches the lateral flow strip 102, the mixture begins to interact with the lateral flow strip 102 (e.g., one or more chemical reactions between the reagent/buffer mixture and the lateral flow strip 102 begins). The device 100 can again be incubated until the interaction is complete, at which time the lateral flow strip 102 can be examined to determine the results of the test. In some implementations, the tube 110 is transparent, so that the lateral flow strip 102 can be visually examined while disposed in the hollow interior 112 of the tube 110. Once the test is complete and the results are recorded, the entire device 100 can be discarded, or the device 100 can be sterilized and prepared for re-use.
In the implementation illustrated in
In
In
The plunger assembly 320 includes a primary plunger 322A and a secondary plunger 322B coupled to a base 321. The plunger assembly 320 is configured to be received within the hollow interior 312 of the cap 310. The primary plunger 322A is longer than the secondary plunger 322B, such that a tip 324A of the primary plunger 322A is spaced farther apart from the base 321 than a tip 324B of the secondary plunger 322B. As discussed in more detail herein, the primary plunger 322A is configured to buckle or compress in response to a sufficient amount of force being applied to the plunger, directed from the tip 324A toward the base 321. Thus, in some implementations, the primary plunger 322A has one or more buckle points. In the illustrated implementation, the buckle points are depicted as notches 326 that are cut out of the primary plunger 322A. When sufficient force is applied to the primary plunger 322A, the primary plunger 322A can bend or crease at these notches 326, such that the primary plunger 322A buckles and can be compressed.
While the illustrated implementation depicts notches 326 cut out of the primary plunger 322A, other types of buckle points can be used. For example, material at portions of the primary plunger 322A could be fabricated to be weaker (such as by adding perforation) instead of being cut out, to cause the primary plunger 322A to buckle at those points. In another example, at least a portion of the primary plunger 322A has a spring-like structure, such that that portion of the primary plunger 322A is configured to compress when the tip 324A of the primary plunger 322A reaches the lower end of the internal cavity 344 (e.g., the upper end of the base 342B).
The reagent insert 330 includes a primary aperture 332A and a secondary aperture 332B defined therethrough. The primary aperture 332A and the secondary aperture 332B generally extend the entire length of the reagent insert 330, from a first end 331A to a second end 331B.
Referring back to
The reaction container 340 is generally formed from a cylindrical wall 342A and a base 342B, that define an internal cavity 344. The upper end of the base 342B (e.g., nearer to the external threads 346) forms the lower end of the internal cavity 344 (e.g., further away from the external threads 346). The internal cavity 344 is configured to hold various substances. In one example, the internal cavity 344 may hold RPA and one or more small beads 345, which can aid in mixing the RPA with other substances during use of the device 300. The sample being tested can also be placed into the reaction container 240 prior to performing the assay, for example via a pipette. The reaction container 340 also contains external threads 346, so that the reaction container 340 can be coupled to the cap 310 via a threaded connection. The external threads 346 of the reaction container 340 are configured to engage with the internal threads 314 of the cap 310, to thereby rotatably couple the reaction container 340 to the cap 310. In some implementations, the reaction container 340 includes an external O-ring configured to form a seal between the exterior of the reaction container 340 and the interior of the cap 310, when the reaction container 340 and the O-ring are positioned within the hollow interior 312 of the cap 310. The internal threads 314 and the external threads 346 could both be left-handed threads or both be right-handed threads. Moreover, in some implementations, the internal threads 314 and the external threads 346 could both be modified such that threads 314 are external threads and threads 346 are internal threads.
In
In
In
The reaction container 420 includes three separate reaction chambers 422A, 422B, and 422C. The reaction chambers 422A-422C are arranged linearly, similarly to the collection swabs 414A-414C, such that reaction chamber 422B is positioned between reaction chamber 422A and reaction chamber 422C along a single linear axis. The reaction chambers 422A and 422B are separated from each other by a wall 424A. The reaction chambers 422B and 422C are separated from each other by a wall 424B. While the reaction container 420 is depicted as a cross-section to show the interior of the reaction chambers 422A-422C, each of the reaction chambers 422A-422C is enclosed on the bottom and the sides, and has a generally cylindrical profile. Each of the reaction chambers 422A-422C has a diameter that is greater than or equal to the width of the rectangular profile of the collection swabs 414A-414C, to allow the collection swabs to be inserted into the reaction chambers 422A-422C. However, the reaction chambers 422A-422C could have a profile having one or more different shapes in other implementations. The device 400 can be formed from any suitable material, such as plastic.
The reaction container 520 has a cylindrical profile, and includes three separate reactions chambers 522A, 522B, and 522C. Similar to the collection swabs 514A-514C, the reaction chambers 522A-522C are arranged circularly, and are generally spaced evenly about the circumference of the cylindrical shape of the reaction container 520. However, the reaction chambers 522A-522C could be spaced differently about the circumference of the cylindrical shape of the reaction container 520 in other implementations. Each of the reaction chambers 522A-522C has a profile that is generally triangular (or pie-shaped) with rounded corners. The smallest dimension of the triangular (or pie-shaped) profile of the reaction chambers 522A-522C is greater than or equal to the width of the rectangular profile of the collection swabs 414A-414C, to allow the collection swabs 514A-514C to be inserted into the reaction chambers 522A-522C. However, the reaction chambers 522A-522C could have a profile having one or more different shapes in other implementations. The device 400 can be formed from any suitable material, such as plastic.
The reaction container 520 is formed by an outer cylindrical wall 524, and three inner walls 526A, 526B, and 526C. Reaction chamber 522A is defined by outer wall 525, inner wall 526A, and inner wall 526C. Reaction chamber 522B is defined by outer wall 525, inner wall 526A, and inner wall 526B. Reaction chamber 522C is defined by outer wall 525, inner wall 526B, and inner wall 526C. Inner wall 526A forms a barrier between reaction chambers 522A and 522B. Inner wall 526B forms a barrier between reaction chambers 522B and 522C. Inner wall 526C forms a barrier between reaction chambers 522A and 522C. Similar to device 400, the device 500 can be formed from any suitable material, such as plastic.
As can be seen, particularly in
The collection swab 514A is disposed in the reaction chamber 522A. The collection swab 514B is disposed in the reaction chamber 522B. The collection swab 514C is disposed in the reaction chamber 522C. The handle 512 covers the upper openings of the reaction chambers 522A-522C, such that the collection assembly 510 acts as a cap for the reaction container 520. While device 500 is shown with three collection swabs 514A-514C and three reaction chambers 522A-522C, the device 500 may include any suitable number of collection swabs and reaction chambers. In the illustrated implementation, each reaction chamber 522A-522C is associated with a corresponding one of the collection swabs 514A-514C, and receives that corresponding one of the collection swabs 514A-514C when the collection assembly 510 is coupled to the reaction container 520 in the assembled configuration. Thus, as shown in
Devices 400 and 500 can be used to perform a variety of different tests on a variety of different samples. In some implementations, the collection swabs 414A-414C and 514A-514C can be used as oral collection swabs, and are configured to collect samples from a human mouth. In other implementations, the collection swabs 414A-414C and 514A-514C can be used as nasal collection swabs, and are configured to collect samples from a human nasal cavity. In additional implementations, the collection swabs 414A-414C and 514A-514C can be used as nasopharyngeal collection swabs, and are configured to collect samples from a human nasopharynx. In further implementations, the collection swabs 414A-414C and 514A-514C can be used as non-human collection swabs, and can be used to collect samples from other sources (such as bacteria samples growing on media plates or from liquid media).
Each of the reaction chambers 422A-422C and/or 522-522C can include any substance (or substances) that may be required to perform a desired test using device 500 or device 500. In some implementations, the reaction chambers of device 400 and/or device 500 are configured to perform the same assay with the same primer. In other implementations, the reaction chambers of device 400 and/or device 500 are configured to perform the same assay but with different primers. In further implementations, the reaction chambers of device 400 and/or device 500 are configured to perform different assays. In additional implementations, the reaction chambers of device 400 and/or device 500 are configured to perform any combination of assays. In some implementations, the substance or substances in the reaction chambers 422A-422C and/or 522A-522C are stored in a blister pack that is configured to be pierced by one of the collection swabs 414A-414C and/or 514A-514C when the collection assembly 410 and/or 510 is inserted into the reaction container 420 and/or 520. The substance or substances in the reaction chambers 422A-422C and/or 522A-522C can be wet, dry (e.g., lyophilized), or a combination of both.
In some implementations, devices 400 and 500 can include a mixing mechanism to allow for homogeneous reaction volumes. If the sample on the collection swab is not mixed evenly with the substance in the reaction chamber, the end test result may not be accurate. In some implementations, the mixing mechanism includes one or more beads that may be made from glass or metal. The beads can be pre-packaged in the reaction chambers. The beads can be configured to mix the sample and the substance in the reaction chamber with or without manual movement of the devices 400 and 500 (e.g., the user shaking or rotating the device). In other implementations, the mixing mechanism includes paddles within the reaction chambers. In some of these other implementations, the paddles are formed on or by the collection swabs. The paddles can be configured to move automatically to mix the sample and the substance, or can be configured to move in response to user action. In further implementations, the devices 400 and 500 can be configured such that user action causes mixing of the sample and the substance in response to manual movement of the devices 400 and 500. For example, the devices 400 and 500 can include one or more openings between separate reaction chambers, such that manual movement by the user causes the sample and/or the substance to flow between the chambers. Thus, devices 400 and 500 can include a plurality of mixing mechanisms that are each configured to aid in mixing (i) any substance in a corresponding one of the reaction chambers with (ii) the sample contained by the corresponding collection swab that is associated with the corresponding one of the reaction chambers.
In some implementations, the reaction chambers include a filter membrane and/or a bead column that act as a sample lysis mechanism. For example, if the test to be performed is a nucleic acid amplification reaction, the sample lysis mechanism allows the sample to undergo an RNA extraction process before the nucleic acid amplification reaction begins. Sample flow through the lysis mechanism can be driven by gravity, molecular forces, air pressured generated by coupling the collection assembly to the reaction container, or any combination thereof.
A second example is an insulated container 610 depicted in
A third example is container 620 depicted in
any one or more of the conductivity (K), cross sectional area (Ac), and distance (dx) of thermal bridges (aluminum, copper, or other highly conducting material) between the device in the central slot 622, the hot reservoir 624A, and the cold reservoir 624B can be adjusted to program specific device temperatures. Highly thermally conductive material can be disposed around the central slot 622 and the hot and cold reservoirs 624A, 624B, but insulated from other components to prevent undesirable heat transfer. Thus, each of the containers 600, 610, and 620 form an isothermal heating block, to provide an isothermal condition to the device and sample being used. Any of the containers 600, 610, and 620 can easily be maintained at a desired temperature, which could be about 42° C. or about 60° C. depending on the assay being performed. Other temperatures can also be used.
In another example depicted in
Containers utilized for performing an assay (such as containers 600, 610, 620, 700, and/or 710) may also include a read-out device that can be coupled to the container, and/or built into the container. The read-out device is configured to indicate to a user the results of the assay. In some implementations, the read-out device is a fluorescent (or color) read-out device that includes a light source (such as an LED), a light filter, and a detector. The light source directs light at the sample, and any light that is emitted by the sample and/or reflects off of the sample will then pass through the filter and be detected by the detector. The result of the assay can be quantified based on properties (such as color, intensity, scattering angle, etc.) of the detected light.
In
Generally, any of these advancement mechanisms can be multiplexed in a single large heating block, providing any of the time, temperature, or reaction advance steps described here. In addition, the block could also include a stepper motor (such as stepper motor 802) or other motor to automatically push the reaction container 840 toward the cap 820 as needed.
Generally, any combination of the heating mechanisms discussed with respect to
Any of devices 100, 200, 300, 400, and 500 can be used to perform a variety of different assays or tests. In some implementations, devices 100-500 can be used to perform an amplification test to detect a target molecule. For example, devices 100-500 can be used to perform a polymerase chain reaction (PCR) test, a loop-mediated isothermal amplification (LAMP) test, a recombinase polymerase amplification (RPA) test, or other amplification tests. PCR tests generally involve changing the temperature of the sample, while LAMP tests and RPA tests are isothermal tests that do not involve changing the temperature of the sample. In these examples, an amplification reaction is performed on the sample, such that a target molecule in the sample is amplified (e.g., multiplied). The presence of that target molecule can then be detected.
In implementations using devices 100, 200, and 300, the lateral flow strips 102, 202, and 302 are used to detect the presence of the target molecule. Generally, the lateral flow strips 102, 202, and 302 include some substance that is configured to indicate the presence of the target molecule. The substance could be a capture reagent (such as a DNA oligonucleotide or an RNA oligonucleotide), a nanoparticle, or other substance. In some implementations, the lateral flow strips 102, 202, and 302 (or one or more portions thereof) may include substances that change color in the presence of the target molecule. This color change can be viewable through the tube 110, the tube 210, or the cap 310. In implementations using devices 400 and 500, the presence of the target molecule can result in the mixed liquids in the reaction chambers changing colors (e.g., a colorimetric reaction). This color change can be viewed through the walls of the reaction containers, which made be made from a transparent or semi-transparent material. Other types of tests or assays can also be performed that utilize different techniques to determine the result of the test or assay.
In some implementations, devices 100-500 can also be used for multiplexing. Multiplexing generally refers to performing multiple different assays or tests at the same time, to detect the presence of a target molecule in multiple different samples, or to amplify and detect multiple different target molecules in a sample or samples. In implementations using any of devices 100-300, the lateral flow strips 102-302 can include multiple physical locations with different capture reagents. The different capture reagents detect the presence of different target molecules. Thus, after the sample has undergone the amplification reaction and reached the lateral flow strip, any area of the lateral flow strip corresponding to a target molecule that was present in the sample and amplified can be detected. In some implementations, multiple different target molecules can be detected in the same sample using a single test. The substance or substances disposed within the devices 100-300 can be configured to amplify a single target molecule in the sample, or multiple target molecules in the sample.
In some implementations using devices 400 or 500, the multiple different reaction chambers can be used to simultaneously test for multiple different target molecules in the same sample. In these implementations, the same sample can be placed into each reaction chamber (e.g., the sample can be collected and a portion of the collected sample is placed into each reaction chamber), and each reaction chamber can have a substance configured to amplify a different target molecule. In other implementations using devices 400 or 500, the multiple different reaction chambers can be used to simultaneously test for the same target molecule in different samples. In these implementations, at least two different samples can be placed into their own reaction chamber, and each reaction chamber can have a substance configured to amplify the same target molecule. This substance may be the same substance for each reaction chamber containing a sample, or could be a different substance for each reaction chamber containing a sample, so long as the substances are configured to amplify the same target molecule. In further implementations using devices 400 or 500, the multiple different reaction chambers can be used to simultaneously test for different target molecules in different samples. In these implementations, at least two reaction chambers contain the same sample (e.g., portions of a sample collected from one source), and a third reaction chamber contains a different sample. The two reaction chambers containing the same sample can contain different substances to amplify different target molecules, while the third reaction chamber can contain any desired substance to amplify any desired target molecule.
A number of different samples can be tested using devices 100-500, such as blood, serum, plasma, urine, semen, mucus, synovial fluid, bile fluid, cerebrospinal fluid, mucosal secretion, effusion, sweat, saliva, etc. The sample could also be a biopsy sample, a tumor sample, or a tissue sample. The sample could further be any combination or mixture of the above-mentioned samples. The target molecule in the sample can be a target protein, a target nucleic acid, or other target molecules. The target nucleic acid can be any desired nucleic acid. Further, the target nucleic acid can include naturally occurring or synthetic nucleic acids. A naturally occurring nucleic acid includes a nucleic acid isolated and/or purified from a natural source.
In some implementations, the target nucleic acid is DNA, e.g., a target DNA. Exemplary target DNAs include, but are not limited to, genomic DNA, viral DNA, cDNA, single-stranded DNA, double-stranded DNA, circular DNA, etc. In some implementations, the target nucleic acid is an RNA, e.g., a target RNA. Generally, the RNA can be any known type of RNA. In some implementations, the target RNA is messenger RNA, ribosomal RNA, Signal recognition particle RNA, Transfer RNA, Transfer-messenger RNA, Small nuclear RNA, Small nucleolar RNA, SmY RNA, Small Cajal body-specific RNA, Guide RNA, Ribonuclease P, Ribonuclease MRP, Y RNA, Telomerase RNA Component, Spliced Leader RNA, Antisense RNA, Cis-natural antisense transcript, CRISPR RNA, Long noncoding RNA, MicroRNA, Piwi-interacting RNA, Small interfering RNA, Short hairpin RNA, Trans-acting siRNA, Repeat associated siRNA, 7SK RNA, Enhancer RNA, Parasitic RNAs, Type, Retrotransposon, Viral genome, Viroid, Satellite RNA, or Vault RNA.
In some implementations, the target RNA can be a viral RNA. As used herein, the term “RNA virus” refers to a virus comprising an RNA genome. In some implementations, the RNA virus is a double-stranded RNA virus, a positive-sense RNA virus, a negative-sense RNA virus, or a reverse transcribing virus (e.g., retrovirus).
In some implementations, the RNA virus is a Group III (i.e., double stranded RNA (dsRNA)) virus. In some implementations, the Group III RNA virus belongs to a viral family selected from the group consisting of: Amalgaviridae, Birnaviridae, Chrysoviridae, Cystoviridae, Endornaviridae, Hypoviridae, Megabirnaviridae, Partitiviridae, Picobirnaviridae, Reoviridae (e.g., Rotavirus), Totiviridae, Quadriviridae. In some implementations, the Group III RNA virus belongs to the Genus Botybirnavirus. In some implementations, the Group III RNA virus is an unassigned species selected from the group consisting of: Botrytis porri RNA virus 1, Circulifer tenellus virus 1, Colletotrichum camelliae filamentous virus 1, Cucurbit yellows associated virus, Sclerotinia sclerotiorum debilitation-associated virus, and Spissistilus festinus virus 1.
In some implementations, the RNA virus is a Group IV (i.e., positive-sense single stranded (ssRNA)) virus. In some implementations, the Group IV RNA virus belongs to a viral order selected from the group consisting of: Nidovirales, Picornavirales, and Tymovirales. In some implementations, the Group IV RNA virus belongs to a viral family selected from the group consisting of: Arteriviridae, Coronaviridae (e.g., Coronavirus, SARS-CoV), Mesoniviridae, Roniviridae, Dicistroviridae, Iflaviridae, Marnaviridae, Picornaviridae (e.g., Poliovirus, Rhinovirus (a common cold virus), Hepatitis A virus), Secoviridae (e.g., sub Comovirinae), Alphaflexiviridae, Betaflexiviridae, Gammaflexiviridae, Tymoviridae, Alphatetraviridae, Alvernaviridae, Astroviridae, Barnaviridae, Benyviridae, Bromoviridae, Caliciviridae (e.g., Norwalk virus), Carmotetraviridae, Closteroviridae, Flaviviridae (e.g., Yellow fever virus, West Nile virus, Hepatitis C virus, Dengue fever virus, Zika virus), Fusariviridae, Hepeviridae, Hypoviridae, Leviviridae, Luteoviridae (e.g., Barley yellow dwarf virus), Polycipiviridae, Narnaviridae, Nodaviridae, Permutotetraviridae, Potyviridae, Sarthroviridae, Statovirus, Togaviridae (e.g., Rubella virus, Ross River virus, Sindbis virus, Chikungunya virus), Tombusviridae, and Virgaviridae. In some implementations, the Group IV RNA virus belongs to a viral genus selected from the group consisting of: Bacillariornavirus, Dicipivirus, Labyrnavirus, Sequiviridae, Blunervirus, Cilevirus, Higrevirus, Idaeovirus, Negevirus, Ourmiavirus, Polemovirus, Sinaivirus, and Sobemovirus. In some implementations, the Group IV RNA virus is an unassigned species selected from the group consisting of: Acyrthosiphon pisum virus, Bastrovirus, Blackford virus, Blueberry necrotic ring blotch virus, Cadicistrovirus, Chara australis virus, Extra small virus, Goji berry chlorosis virus, Hepelivirus, Jingmen tick virus, Le Blanc virus, Nedicistrovirus, Nesidiocoris tenuis virus 1, Niflavirus, Nylanderia fulva virus 1, Orsay virus, Osedax japonicus RNA virus 1, Picalivirus, Plasmopara halstedii virus, Rosellinia necatrix fusarivirus 1, Santeuil virus, Secalivirus, Solenopsis invicta virus 3, Wuhan large pig roundworm virus. In some implementations, the Group IV RNA virus is a satellite virus selected from the group consisting of: Family Sarthroviridae, Genus Albetovirus, Genus Aumaivirus, Genus Papanivirus, Genus Virtovirus, and Chronic bee paralysis virus.
In some implementations, the RNA virus is a Group V (i.e., negative-sense ssRNA) virus. In some implementations, the Group V RNA virus belongs to a viral phylum or subphylum selected from the group consisting of: Negarnaviricota, Haploviricotina, and Polyploviricotina. In some implementations, the Group V RNA virus belongs to a viral class selected from the group consisting of: Chunqiuviricetes, Ellioviricetes, Insthoviricetes, Milneviricetes, Monjiviricetes, and Yunchangviricetes. In some implementations, the Group V RNA virus belongs to a viral order selected from the group consisting of: Articulavirales, Bunyavirales, Goujianvirales, Jingchuvirales, Mononegavirales, Muvirales, and Serpentovirales. In some implementations, the Group V RNA virus belongs to a viral family selected from the group consisting of: Amnoonviridae (e.g., Taastrup virus), Arenaviridae (e.g., Lassa virus), Aspiviridae, Bornaviridae (e.g., Borna disease virus), Chuviridae, Cruliviridae, Feraviridae, Filoviridae (e.g., Ebola virus, Marburg virus), Fimoviridae, Hantaviridae, Jonviridae, Mymonaviridae, Nairoviridae, Nyamiviridae, Orthomyxoviridae (e.g., Influenza viruses), Paramyxoviridae (e.g., Measles virus, Mumps virus, Nipah virus, Hendra virus, and NDV), Peribunyaviridae, Phasmaviridae, Phenuiviridae, Pneumoviridae (e.g., RSV and Metapneumovirus), Qinviridae, Rhabdoviridae (e.g., Rabies virus), Sunviridae, Tospoviridae, and Yueviridae. In some implementations, the Group V RNA virus belongs to a viral genus selected from the group consisting of: Anphevirus, Arlivirus, Chengtivirus, Crustavirus, Tilapineviridae, Wastrivirus, and Deltavirus (e.g., Hepatitis D virus).
In some implementations, the RNA virus is a Group VI RNA virus, which comprise a virally encoded reverse transcriptase. In some implementations, the Group VI RNA virus belongs to the viral order Ortervirales. In some implementations, the Group VI RNA virus belongs to a viral family or subfamily selected from the group consisting of: Belpaoviridae, Caulimoviridae, Metaviridae, Pseudoviridae, Retroviridae (e.g., Retroviruses, e.g. HIV), Orthoretrovirinae, and Spumaretrovirinae. In some implementations, the Group VI RNA virus belongs to a viral genus selected from the group consisting of: Alpharetrovirus (e.g., Avian leukosis virus; Rous sarcoma virus), Betaretrovirus (e.g., Mouse mammary tumour virus), Bovispumavirus (e.g., Bovine foamy virus), Deltaretrovirus (e.g., Bovine leukemia virus; Human T-lymphotropic virus), Epsilonretrovirus (e.g., Walleye dermal sarcoma virus), Equispumavirus (e.g., Equine foamy virus), Felispumavirus (e.g., Feline foamy virus), Gammaretrovirus (e.g., Murine leukemia virus; Feline leukemia virus), Lentivirus (e.g., Human immunodeficiency virus 1; Simian immunodeficiency virus; Feline immunodeficiency virus), Prosimiispumavirus (e.g., Brown greater galago prosimian foamy virus), and Simiispumavirus (e.g., Eastern chimpanzee simian foamy virus).
In some implementations, the RNA virus is selected from influenza virus, human immunodeficiency virus (HIV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In some implementations, the RNA virus is influenza virus. In some implementations, the RNA virus is immunodeficiency virus (HIV). In some implementations, the RNA virus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
In some implementations, the viral RNA is an RNA produced by a virus with a DNA genome, i.e., a DNA virus. As a non-limiting example the DNA virus is a Group I (dsDNA) virus, a Group II (ssDNA) virus, or a Group VII (dsDNA-RT) virus.
In some implementations, at least one member of the plurality of target nucleic acids is single-stranded. In some implementations, at least one member of the plurality of target nucleic acids is double-stranded. In some implementations, at least one member of the plurality of target nucleic acids is RNA. In some implementations, at least one member of the plurality of target nucleic acids is DNA. In some implementations, at least one member of the plurality of target nucleic acids is a viral nucleic acid. In some implementations, at least one member of the plurality of target nucleic acids is a first viral nucleic acid and at least one member of the plurality of target nucleic acids is a second viral nucleic acid. For example, the first and second viral nucleic acids are from different viruses. In some implementations, at least one member of the plurality of target nucleic acids is a viral RNA. In some implementations, at least one member of the plurality of target nucleic acids is a viral DNA.
In some implementations, the target nucleic acid includes bacterial DNA, bacterial RNA, viral DNA, viral RNA, fungal DNA, fungal RNA, eukaryotic DNA, eukaryotic RNA, prokaryotic DNA, prokaryotic RNA, or any combination thereof.
In some implementations, multiple devices can be used simultaneously in an array to test multiple different samples. The devices can be arranged so that they can all be simultaneously physically manipulated, for example to advance the reaction (devices 100-300) or too couple the collection assembly to the reaction chamber (devices 400 and 500).
In some implementations, devices 100-500 can be single-use devices. In these implementations, devices 100-500 can include a one-way closure mechanism. The one-way closure mechanism allows the reaction chamber to be coupled to the rest of the device (e.g., the tube and/or cap, or the collection assemblies) once the samples are collected and deposited into the reaction chamber. The one-way closure mechanism then prevents the devices from being disassembled after the assay or test has been performed, so that amplified target molecules in the devices do not pose any contamination risk. In other implementations however, devices 100-500 could be reusable.
The description of implementations of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific implementations of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative implementations may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various implementations described herein can be combined to provide further implementations. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further implementations of the disclosure. These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.
This application claims the benefit of, and priority to, U.S. Provisional Patent Application No. 63/083,640, filed on Sep. 25, 2020; U.S. Provisional Patent Application No. 63/082,776, filed on Sep. 24, 2020; U.S. Provisional Patent Application No. 63/046,424, filed on Jun. 30, 2020; and U.S. Provisional Patent Application No. 63/043,232, filed on Jun. 24, 2020, each of which is hereby incorporated by reference herein in its entirety.
This invention was made with U.S. Government support under grant nos. 1DP1GM133052-01, 5DP1GM133052-02, and 1R21CA235421-01 awarded by the National Institutes of Health. The U.S. Government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US21/38930 | 6/24/2021 | WO |
Number | Date | Country | |
---|---|---|---|
63043232 | Jun 2020 | US | |
63046424 | Jun 2020 | US | |
63082776 | Sep 2020 | US | |
63083640 | Sep 2020 | US |